FINWIRES · TerminalLIVE
FINWIRES

Hershey's First-Quarter Results Likely to be Strong Amid 'Solid' Consumption Trends, RBC Says

作者

-- Hershey (HSY) is expected to post strong first-quarter results amid "solid" consumption trends, while the chocolate maker will likely affirm its 2026 outlook, RBC Capital Markets said Tuesday.

Scanner data indicate "solid" consumption at the total company level in the quarter, driven by strong gains in confection and salty snacks, the brokerage said in a note to clients. Hershey is scheduled to report first-quarter results Thursday.

"With an earlier Easter, confection data for the final week of March is up strong (over high-teen percentage)," Nik Modi, RBC's co-head of global consumer and retail research, said. "This level of growth would suggest that (Hershey) will be able to clear topline growth expectations."

RBC expects first-quarter earnings of $2.08 a share on revenue of $3.03 billion. Wall Street is looking for $2.05 and $3.03 billion, respectively, according to the note. Although the three-month period was guided to be "the strongest quarter on the topline," margins are expected to be pressured by high cost of inventory, Modi said.

The brokerage expects Hershey to reaffirm its full-year outlook given that the company is just one quarter through its fiscal year and maintained the outlook just recently. "That said, we see a more neutral risk to reward given the high bar that (Hershey) set for itself this year," Modi wrote.

Late last month, company said it continued to expect full-year adjusted EPS to grow 30% to 35% and net sales to rise 4% to 5%.

The management's tone was positive at its investor day, with its long-term outlook suggesting the company has EPS visibility through 2027, RBC said. "With that said, the proof is now in the pudding on whether (Hershey's) strategy can revert ongoing volume declines and market share losses."

The brokerage has a sector perform rating on Hershey's stock with a $212 price target.

Price: $187.29, Change: $+0.80, Percent Change: +0.43%

相關文章

Asia

Rua Bioscience指出,在監管審查期間,澳洲醫用大麻處方量出現「顯著萎縮」。

Rua Bioscience(NZE:RUA)週三向紐西蘭證券交易所提交的文件顯示,由於澳洲藥品管理局(TGA)正在對未經批准的產品進行安全性審查,因此澳洲醫用大麻處方量出現「顯著萎縮」。 然而,Rua補充道,儘管近期國際情勢發展以及全球經濟放緩的討論,醫用大麻在國際市場,尤其是在歐洲,正展現出「強勁的成熟和成長跡象」。 根據文件顯示,該公司近期在加拿大(僅次於美國的世界第二大大麻市場)成立了RUA Genetics公司,進一步拓展了在德國、澳洲、紐西蘭、捷克和英國的業務。 在澳大利亞,該公司預計監管審查完成後市場將出現重置,並正努力將其產品引入新的連鎖診所。 此外,Rua計劃在未來幾個月內將多款產品引入紐西蘭市場,並正在籌備計劃於5月在捷克推出的產品。此外,該公司正尋求在英國擴張,並計劃透過新的管道和連鎖診所整合其基因技術。 在德國,該公司認為,由於先前審查期間分銷商減少了庫存並縮減了進口規模,因此不太可能出現重大的監管變化,市場對穩定可靠的供應商需求強勁。 Rua表示,德國市場依然競爭激烈,並持續展現強勁的成長動能。

$NZE:RUA
Treasury

市場動態:英偉達關聯資料中心透過發行垃圾債券籌集46億美元

根據彭博社週二援引知情人士報道,與英偉達(NVDA)相關的內華達州資料中心項目透過發行垃圾債券籌集了45.9億美元,凸顯了人工智慧基礎設施融資交易的增加。 報道稱,這筆交易由Tract Capital Management和Fleet Data Centers支持,五年期債券的殖利率為6.74%。 該項目位於內華達州,裝置容量為200兆瓦,預計將租給英偉達。 彭博社指出,此次交易定價正值資料中心相關股票和債券市場整體波動之際,因為人們越來越擔心人工智慧相關支出的快速成長能否帶來預期回報。 英偉達尚未回覆的置評請求。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)

$NVDA
Asia

Qoria稱挪威銀行不再是主要股東。

根據週三提交給澳洲證券交易所的文件顯示,Qoria(ASX:QOR)收到通知,挪威銀行自周一起不再是該公司的主要股東。 先前的文件顯示,挪威銀行於4月24日成為該公司的主要股東,持有5.02%的投票權。

$ASX:QOR